TY - JOUR
T1 - Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol
AU - PanCareLIFE Consortium
AU - van der Kooi, Anne-Lotte L. F.
AU - Clemens, Eva
AU - Broer, Linda
AU - Zolk, Oliver
AU - Byrne, Julianne
AU - Campbell, Helen
AU - van den Berg, Marleen
AU - Berger, Claire
AU - Calaminus, Gabriele
AU - Dirksen, Uta
AU - Winther, Jeanette Falck
AU - Fosså, Sophie D.
AU - Grabow, Desiree
AU - Haupt, Riccardo
AU - Kaiser, Melanie
AU - Kepak, Tomas
AU - Kremer, Leontien
AU - Kruseova, Jarmila
AU - Modan-Moses, Dalit
AU - Ranft, Andreas
AU - Spix, Claudia
AU - Kaatsch, Peter
AU - Laven, Joop S. E.
AU - van Dulmen-den Broeder, Eline
AU - Uitterlinden, André G.
AU - van den Heuvel-Eibrink, Marry M.
AU - O'Brien, Kylie
AU - Langer, Thorsten
AU - Borgmann-Staudt, Anja
AU - Am Zehnhoff-Dinnesen, Antoinette
AU - Kuehni, Claudia
AU - Baust, Katja
AU - van Leeuwen, Floor
AU - Strauss, Gabriele
AU - Haupt, R.
AU - Garré, M. L.
AU - Leiper, Alison
AU - Lackner, H.
AU - Panasiuk, Anna
AU - Krawczuk-Rybak, Maryna
AU - Kunstreich, Marina
AU - Cario, Holger
AU - Bielack, Stefan
AU - Stefanowicz, Joanna
AU - Grandage, Victoria
PY - 2018
Y1 - 2018
N2 - BACKGROUND: Improved risk stratification, more effective therapy and better supportive care have resulted in survival rates after childhood cancer of around 80% in developed countries. Treatment however can be harsh, and three in every four childhood cancer survivors (CCS) develop at least one late effect, such as gonadal impairment. Gonadal impairment can cause involuntary childlessness, with serious consequences for the well-being of CCS. In addition, early menopause increases the risk of comorbidities such as cardiovascular disease and osteoporosis. Inter-individual variability in susceptibility to therapy related gonadal impairment suggests a role for genetic variation. Currently, only one candidate gene study investigated genetic determinants in relation to gonadal impairment in female CCS; it yielded one single nucleotide polymorphism (SNP) that was previously linked with the predicted age at menopause in the general population of women, now associated with gonadal impairment in CCS. Additionally, one genome wide association study (GWAS) evaluated an association with premature menopause, but no GWAS has been performed using endocrine measurements for gonadal impairment as the primary outcome in CCS.
AB - BACKGROUND: Improved risk stratification, more effective therapy and better supportive care have resulted in survival rates after childhood cancer of around 80% in developed countries. Treatment however can be harsh, and three in every four childhood cancer survivors (CCS) develop at least one late effect, such as gonadal impairment. Gonadal impairment can cause involuntary childlessness, with serious consequences for the well-being of CCS. In addition, early menopause increases the risk of comorbidities such as cardiovascular disease and osteoporosis. Inter-individual variability in susceptibility to therapy related gonadal impairment suggests a role for genetic variation. Currently, only one candidate gene study investigated genetic determinants in relation to gonadal impairment in female CCS; it yielded one single nucleotide polymorphism (SNP) that was previously linked with the predicted age at menopause in the general population of women, now associated with gonadal impairment in CCS. Additionally, one genome wide association study (GWAS) evaluated an association with premature menopause, but no GWAS has been performed using endocrine measurements for gonadal impairment as the primary outcome in CCS.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054092877&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30257669
U2 - https://doi.org/10.1186/s12885-018-4834-3
DO - https://doi.org/10.1186/s12885-018-4834-3
M3 - Article
C2 - 30257669
SN - 1471-2407
VL - 18
SP - 930
JO - BMC Cancer
JF - BMC Cancer
IS - 1
ER -